Immune-Mediated Inflammation Promotes Subclinical Atherosclerosis in Recent-Onset Psoriatic Arthritis Patients without Conventional Cardiovascular Risk Factors

Frers, Rodolfo A. Kölliker; Cosentino, Vanesa; Tau, Julia; Kerzberg, Eduardo; Urdapilleta, Adriana; Chiocconi, Monica; Kogan, Nora; Otero‐Losada, Matilde; Capani, Francisco

doi:10.3389/fimmu.2018.00139

Cited by 26 publications

(20 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Kolliker Frers et al have demonstrated that pro-atherogenic inflammation marker C-reactive protein (CRP) and soluble intercellular adhesion molecule-1 levels are increased also in psoriatic patients with no CV history or traditional CV risk factors, compared with healthy subjects, as well as in patients with recent-onset PsA, even in the absence of CV risks. These data reinforce the concept that that the degree of atherosclerosis tendency might be related to the amount of the inflammatory psoriatic burden and highlight the importance of primary prevention in Pso also in those psoriatic patients with no history of CV events ( 24 ).…”

Section: Psoriasis and Cardiovascular (Cv) Eventssupporting

confidence: 83%

Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows

et al. 2018

View full text Add to dashboard Cite

Nowadays, it is well established a link between psoriasis and cardiovascular (CV) diseases. A series of different overlapping mechanisms including inflammation, homeostasis dysregulation, and genetic susceptibility are thought to underlie this association. Advances in understanding the molecular patterns involved in the complex scenario of psoriasis have highlighted a tight correlation with atherosclerosis. Indeed, common profiles are shared in term of inflammatory cytokines and cell types. In the last decade, the management of psoriasis patients has been revolutionized with the introduction of biological therapies, such as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-12/23, and IL-17 inhibitors. In clinical setting, the effectiveness of these therapies as well as the incidence of CV events is related to the type of biologics. In particular, anti-TNF-α agents seem to reduce these events in psoriasis patients whereas anti-IL-12/23 agents related CV events reduction still remain to clarify. It has to be taken into account that IL-12/23 inhibitors have a shorter post-marketing surveillance period. An even more restricted observational time is available for anti-IL-17 agents. IL-17 is associated with psoriasis, vascular disease, and inflammation. However, IL-17 role in atherosclerosis is still debated, exerting both pro-atherogenic and anti-atherogenic effects depending on the specific context. In this review, we will discuss the differences between the onset of CV events in psoriasis patients, referred to specific biological therapy and the underlying immunological mechanism. Given the development of new therapeutic strategies, the investigation of these inhibitors impact on heart failure outcome is extremely important.

show abstract

Section: Psoriasis and Cardiovascular (Cv) Eventssupporting

confidence: 83%

Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Elevated levels of sCD54 and MIF in the serum of patients with psoriasis and control over their dynamics have prognostic significance in determining both the severity of the disease and the effectiveness of the therapy. The obtained data are consistent with the results of other researchers, indicating the value of serum markers sCD54 (31) and MIF (32, 33) in the pathogenesis of psoriasis, and can be considered as potential biomarkers and targets for immunomodulating therapies for psoriasis. Standardized serum markers measurement is available for clinical use and analysis of secreted protein after treatment by immunomodulators would offer a prognostic factor of the therapy effectiveness.…”

Section: Resultssupporting

confidence: 91%

Pathogenetic Therapy of Psoriasis by Muramyl Peptide

2019

View full text Add to dashboard Cite

Psoriasis is a multifactorial disease with a dysregulation in immune system. The aim of this study was to survey the clinical efficacy and safety of muramyl peptide—the ligand of the receptors of innate immunity (drug Licopid, AO Peptek, Moscow, Russia) in patients with psoriasis. The effect of muramyl peptide on 86 patients with different severity of plaque psoriasis was tested. The Psoriasis Area and Severity Index (PASI), cytokine status and production of nitric oxide in blood serum, and the subsequent course of psoriasis have been evaluated. Evaluation of significance of observed differences was presented by the Student's t -test. As a result of the treatment, clinical cure or improvement was detected in 98.2% of patients ( p < 0.05), while 24.4% had a complete cure. Subsequent observations during 4 years showed that patients who received muramyl peptide statistically significantly increased relapse-free period. Moreover, subsequent relapses of the disease after treatment with muramyl peptide were in much more milder form in the cases of mild psoriasis. The conducted studies showed that monotherapy with muramyl peptide stopped the clinical manifestations of psoriasis, normalized the processes of cytokine-dependent [interleukin (IL)−4, IL-10, IL-12, tumor necrosis factor alpha (TNF-α)] regulation of the immune response and nonspecific resistance, expressed in a decreasing amount of serum antigens sCD54 [soluble intercellular adhesion molecule-1 (sICAM-1)] to reference values ( p ≤ 0.01). Taken together, our research demonstrated the effectiveness of therapy with muramyl peptide and moreover, that elevated levels of sCD54 and MIF ( p ≤ 0.01) in the serum of patients with psoriasis considered as potential biomarkers of the severityof psoriasis and control over their dynamics have prognostic significance in determining the effectiveness of the therapy.

show abstract

“…Regarding SLE, data is more limited, but studies have shown increased levels of certain soluble endothelial damage biomarkers, such as ICAM-1 and thrombomodulin (TM) in SLE women and VCAM-1 in patients with lupus nephritis [ 126 , 127 ] Similarly, AS studies indicate that increased levels of ICAM-1, TM and IL-6, as well as increased ADMA serum concentrations are not correlated however with disease activity [ 128 , 129 , 130 ]. In PsA, both ICAM-1 and VCAM-1 levels have been found to be increased compared to controls and ICAM and IL6 were correlated with Cimt [ 131 , 132 ].…”

Section: Immunological Mechanismsmentioning

confidence: 99%

Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases

Arida

Protogerou

Kitas

et al. 2018

IJMS

136

View full text Add to dashboard Cite

Patients with Chronic Inflammatory Rheumatic diseases (CIRD) are at increased risk of cardiovascular disease (CVD), ascribed not only to classical risk factors, but also to the presence of chronic systemic inflammatory response. Αtherosclerosis, the cornerstone of CVD, is known to be accelerated in CIRD; rheumatoid arthritis promotes atheromatosis and associates with preclinical atherosclerosis equivalent to Diabetes Mellitus, which also seems to apply for systemic lupus erythematosus. Data on ankylosing spondylitis and psoriatic arthritis, albeit more limited, also support an increased CV risk in these patients. The association between inflammation and atherosclerosis, has been thoroughly investigated in the last three decades and the role of inflammation in the pathogenesis and progression of atherogenesis has been well established. Endothelial dysfunction, oxidative stress in vascular endothelial cells and macrophage accumulation, toll-like receptor signaling, NLPR-3 formation and subsequent pro-inflammatory cytokine production, such as TNFa, IL-1β, IL-6, and TNF-like cytokine 1A, are few of the mechanisms implicated in the atherogenic process. Moreover, there is evidence that anti-inflammatory biologic drugs, such as anti-TNF and anti-IL1β agents, can decelerate the atherogenic process, thus setting new therapeutic targets for early and effective disease control and suppression of inflammation, in addition to aggressive management of classical CV risk factors.

show abstract

Immune-Mediated Inflammation Promotes Subclinical Atherosclerosis in Recent-Onset Psoriatic Arthritis Patients without Conventional Cardiovascular Risk Factors

Cited by 26 publications

References 62 publications

Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows

Psoriasis, Cardiovascular Events, and Biologics: Lights and Shadows

Pathogenetic Therapy of Psoriasis by Muramyl Peptide

Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases

Contact Info

Product

Resources

About